HOPE-Epilepsy Trial

High Dose Omega 3 Fatty Acids Supplementation in Patients With Epilepsy : The HOPE-Epilepsy Trial

Status

Suspended

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01744275

Acronym

HOPE-Epilepsy

Enrollment

370

Registered

2012-12-06

Start date

2013-07-31

Completion date

2016-07-31

Last updated

2014-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Keywords

Epilepsy, Omega 3 fatty acids

Brief summary

This a multi-center study to examine whether supplementation with omega 3 fatty acids will reduce seizure frequency in patients with epilepsy .

Interventions

DIETARY_SUPPLEMENTOmega 3 fatty acids

DIETARY_SUPPLEMENTcorn oil

Placebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Patients with active Epilepsy

Exclusion criteria

* pregnant women or breastfeeding

Design outcomes

Primary

Measure	Time frame	Description
Seizure Frequency	18 months	number of seizures during the treatment period

Secondary

Measure	Time frame	Description
categorized seizure frequency	18 months	number of crises categorized as: generalized, focal with disconnection and focal without disconnection
Percentage of overall seizure frequency modification	18 months	percentage of reduction or increase in seizure frequency from baseline til the end of treatment period
Time Free of seizures during treatment	12 months	—
Reduction in seizure frequency	12 months	—
Quality of Life	12 months	—

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026